SGMT
NASDAQ · Biotechnology
Sagimet Biosciences Inc-A
$7.73
-0.06 (-0.77%)
Open$7.70
Previous Close$7.79
Day High$7.84
Day Low$7.42
52W High$11.41
52W Low$4.50
Volume—
Avg Volume1.21M
Market Cap431.96M
P/E Ratio—
EPS$-1.34
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
-61.2% upside
Current
$7.73
$7.73
Target
$3.00
$3.00
$2.20
$3.00 avg
$3.42
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 28.61M | 29.26M | 29.39M |
| Net Income | 3.39M | 4.16M | 4.24M |
| Profit Margin | 11.8% | 14.2% | 14.4% |
| EBITDA | 5.59M | 5.60M | 5.84M |
| Free Cash Flow | 4.74M | 2.94M | 4.50M |
| Rev Growth | +24.7% | +14.4% | -5.6% |
| Debt/Equity | 0.41 | 0.48 | 0.36 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |